Ibio Stock Price, News & Analysis

iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time. This virtual presentation will be broadcasted live and archived on the iBio website under the 'News & Events' section.

iBio is known for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals, including treatments for cancers and infectious diseases.

Pipeline Therapeutics announced the appointment of Eef Schimmelpennink to its Board of Directors. With nearly 25 years of experience in the biotechnology sector, he aims to enhance the company’s efforts in neuroregeneration. Schimmelpennink has held prominent roles, including CEO of Pfenex and LENZ Therapeutics. His leadership is expected to advance Pipeline's promising portfolio, which includes two clinical candidates, PIPE-307 and PIPE-505, targeting neurological conditions. This strategic addition to the board could bolster the company's growth trajectory in the biopharmaceutical industry.

iBio, Inc. (NYSEA:IBIO) reported its financial results for the quarter ending December 31, 2021. The company added six new immuno-oncology assets to its pipeline and is advancing its COVID-19 vaccine candidate, IBIO-202, toward clinical trials. Revenues were approximately $0.2 million, a 76% decrease from the previous year, while R&D and G&A expenses increased by 40% and 48%, respectively. The net loss for the quarter was approximately $11.9 million. iBio expects adequate cash to fund operations through September 30, 2023.

iBio, Inc. (NYSEA:IBIO) announced it will report fiscal 2022 second quarter financial results on February 14, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results and future corporate updates. iBio specializes in next-generation biopharmaceuticals, utilizing its innovative FastPharming Manufacturing System® for sustainable, plant-based biologics. The company aims to advance treatments for cancers and other diseases through high-quality monoclonal antibodies and proteins.

iBio Updates on IBIO-202 COVID-19 Vaccine Development

iBio, Inc. (IBIO) announced progress on its COVID-19 vaccine, IBIO-202, which targets the nucleocapsid protein. Following FDA feedback, the company will conduct IND-enabling challenge studies and aims to submit an IND application by year-end 2022. This second-generation vaccine seeks to overcome waning immunity associated with first-generation vaccines that focus on the spike protein. iBio's research indicates that the N protein could stimulate a more durable immune response against emerging variants.

iBio, Inc. (NYSE: IBIO) announced its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will provide a pre-recorded presentation accessible to all registered attendees and on its website beginning January 10. iBio specializes in next-generation biopharmaceuticals through its FastPharming Manufacturing System, which integrates vertical farming and automated hydroponics to produce high-quality proteins. The firm is focused on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases.

iBio, Inc. (NYSE: IBIO) has partially adjourned its 2021 Annual Meeting of Shareholders to allow further voting on two key proposals: a Reverse Stock Split and a Change in Authorized Shares. As of now, shareholders are supporting these proposals by a 2-to-1 margin. The Annual Meeting will reconvene on January 31, 2022, at 9:00 a.m. Eastern time. The company encourages those who have not yet voted or who voted against the proposals to reconsider their stance.

iBio, a developer of biopharmaceuticals, announced that its 2021 Annual Shareholders meeting is set for December 22, 2021, at 9:00 AM EST. The meeting will address two critical proposals: a reverse stock split and an increase in authorized shares. Currently, 64% and 67% of shareholders have voted in favor, but additional votes are necessary for approval. iBio encourages shareholders who have not yet voted to participate. The company is recognized for its sustainable, plant-based FastPharming Manufacturing System, aimed at developing treatments for various diseases.

iBio announced the partial adjournment of its annual meeting of stockholders to December 22, 2021, with over 60% of shares voting in favor of a reverse stock split and authorized share decrease. Proposals 4 and 5 received 64% and 67% support, respectively. Both Glass Lewis and ISS recommended approving these measures. The Company aims to secure the requisite majority from all outstanding shares to facilitate its growth strategy while encouraging additional votes from shareholders who have not yet voted.